Prospective, multicenter randomized GITMO/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: the superior disease control of R-HDS does not translate into an overall survival advantageMarco Ladetto, Corrado Tarella, Alessandro M. Gianni et al.|Blood|2008Cited by 253
Risk Factors for the Development of Secondary Malignancy After High-Dose Chemotherapy and Autograft, With or Without Rituximab: A 20-Year Retrospective Follow-Up Study in Patients With LymphomaCorrado Tarella, Alessandro Rambaldi, Roberto Passera et al.|Journal of Clinical Oncology|2010Cited by 167
Minimal Residual Disease Detection by Droplet Digital PCR in Multiple Myeloma, Mantle Cell Lymphoma, and Follicular LymphomaDaniela Drandi, Marco Ladetto, Lenka Kubiczkova-Besse et al.|Journal of Molecular Diagnostics|2015Cited by 132
Rituximab Improves the Efficacy of High-Dose Chemotherapy With Autograft for High-Risk Follicular and Diffuse Large B-Cell Lymphoma: A Multicenter Gruppo Italiano Terapie Innnovative nei Linfomi SurveyCorrado Tarella, Alessandro Rambaldi, Manuela Zanni et al.|Journal of Clinical Oncology|2008Cited by 72
Multiple myeloma shows no intra-disease clustering of immunoglobulin heavy chain genesSimone Ferrero, Marco Ladetto, Daniela Capello et al.|Haematologica|2011Cited by 16